Supplementary Table 6. Clinical outcomes according to the SGLT2i use during admission in patients with ischemic stroke

	No SGLT2i (n=288)	SGLT2i (n=83)	OR (95% CI) or β (SE)	*P*
END	28 (9.7)	8 (9.6)	0.99 (0.43–2.26)	0.982
NIHSS at discharge	2 [1; 5]	2 [1; 3.5]	-0.565 (0.946)*	0.551
mRS at discharge	2 [1; 3]	1 [1; 3]	1.30 (0.84–2.03)†	0.237
Favorable outcome at discharge	187 (64.9)	57 (68.7)	1.18 (0.70–2.00)	0.527
Excellent outcome at discharge	128 (44.4)	42 (50.6)	1.28 (0.79–2.09)	0.322
mRS at 3 months	2 [0; 3]	1 [0; 3]	1.54 (0.99–2.40)†	0.055
Favorable outcome at 3 months	188 (65.3)	60 (72.3)	1.39 (0.81–2.38)	0.233
Excellent outcome at 3 months	141 (49.0)	51 (61.4)	1.66 (1.01–2.74)	0.046

The data are presented as n (%) or median [interquartile range].
SGLT2i, sodium-glucose cotransporter 2 inhibitor; OR, odds ratio; CI, confidence interval; β, unstandardized coefficient; SE, standard error; END, early neurological deterioration; NIHSS, National Institutes of Health Stroke Scale; mRS, modified Rankin Scale.
*Unstandardized coefficient and standard error by linear regression; †Proportional odds ratios for favorable mRS scores by ordinal logistic regression.

Supplementary Table 7. Comparison of FDG uptake in various regions according to SGLT2i use during the acute phase in patients with ischemic stroke

	Nondiabetic control (n=26)	Diabetic patients without SGLT2i (n=8)	Diabetic patients with SGLT2i (n=6)	*P*
Age (yr)	61.2±15.2	70.1±11.1	67.5±10.0	0.239
Male sex	13 (50.0)	7 (87.5)	4 (66.7)	0.153
HbA1c (%)	5.75±0.39	7.11±0.62	7.43±0.71	<0.001
eGFR (mL/min/1.73 m^2)	86.7±17.8	76.6±21.5	83.4±20.4	0.423
FDG uptake (TBR)				
Amygdala	3.55±0.84	2.95±0.58	2.96±0.72	0.089
Distal ICA	1.02±0.13	0.95±0.15	1.01±0.10	0.437
Proximal ICA	1.12±0.12	1.08±0.09	1.13±0.09	0.604
Spleen	1.18±0.23	1.06±0.11	1.12±0.07	0.307
Liver	1.00±0.10	0.94±0.15	0.99±0.07	0.300
Bone marrow	1.20±0.89	0.86±0.17	0.92±0.08	0.434
Psoas muscle	0.37±0.06	0.33±0.13	0.43±0.11	0.110
Visceral adipose tissue	0.22±0.07	0.18±0.06	0.17±0.04	0.110
Brown adipose tissue	0.25±0.06	0.20±0.03	0.25±0.03	0.044
Subcutaneous adipose tissue	0.13±0.05	0.10±0.02	0.15±0.03	0.109

The data are presented as n (%) or mean±standard deviation.
FDG, fluorodeoxyglucose; SGLT2i, sodium-glucose cotransporter 2 inhibitor; HbA1c, hemoglobin A1c; eGFR, estimated glomerular filtration rate; TBR, target-to-background ratio; ICA, internal carotid artery.

https://doi.org/10.5853/jos.2023.04056